Advanced Magnetics targets pancreas:
This article was originally published in Clinica
Diagnostic imaging of the pancreas is the initial aim of an R&D project between Advanced Magnetics and Massachusetts General Hospital. The product development agreement, whereby MGH will receive a minimum payment of $300,000, covers organ-specific, receptor-directed, superparamagnetic iron oxides for use as MRI contrast agents. Initial collaboration will focus on the pancreas - an "extremely difficult" organ to image, says Advanced Magnetics. Cancer of the pancreas affects 40,000 Americans each year.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.